Aecor.bio is a company focused on developing novel peptide therapies to overcome treatment resistance, a major challenge in many diseases. They use AI-driven methods to design and synthesize peptides targeting disrupted gene expression responsible for treatment resistance at the cellular level. Their approach includes synthesizing thousands of unique peptides with proprietary algorithms, identifying gene expression changes linked to resistance, and repairing cellular micro-environments to reverse these changes.
